AU2006278571B2 - Compositions exhibiting improved flowability - Google Patents

Compositions exhibiting improved flowability Download PDF

Info

Publication number
AU2006278571B2
AU2006278571B2 AU2006278571A AU2006278571A AU2006278571B2 AU 2006278571 B2 AU2006278571 B2 AU 2006278571B2 AU 2006278571 A AU2006278571 A AU 2006278571A AU 2006278571 A AU2006278571 A AU 2006278571A AU 2006278571 B2 AU2006278571 B2 AU 2006278571B2
Authority
AU
Australia
Prior art keywords
composition
powder
solid material
modified nanoparticles
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006278571A
Other languages
English (en)
Other versions
AU2006278571A1 (en
Inventor
Jimmie R. Baran Jr.
Madeline P. Shinbach
James S. Stefely
Stephen W. Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of AU2006278571A1 publication Critical patent/AU2006278571A1/en
Application granted granted Critical
Publication of AU2006278571B2 publication Critical patent/AU2006278571B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2006278571A 2005-08-05 2006-08-04 Compositions exhibiting improved flowability Ceased AU2006278571B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70582105P 2005-08-05 2005-08-05
US60/705,821 2005-08-05
PCT/US2006/030278 WO2007019229A1 (en) 2005-08-05 2006-08-04 Compositions exhibiting improved flowability

Publications (2)

Publication Number Publication Date
AU2006278571A1 AU2006278571A1 (en) 2007-02-15
AU2006278571B2 true AU2006278571B2 (en) 2011-11-24

Family

ID=37311861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006278571A Ceased AU2006278571B2 (en) 2005-08-05 2006-08-04 Compositions exhibiting improved flowability

Country Status (7)

Country Link
US (1) US8062670B2 (OSRAM)
EP (1) EP1917301B1 (OSRAM)
JP (2) JP5694643B2 (OSRAM)
CN (1) CN101243130B (OSRAM)
AU (1) AU2006278571B2 (OSRAM)
CA (1) CA2617909C (OSRAM)
WO (1) WO2007019229A1 (OSRAM)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
JP2010514649A (ja) * 2006-12-21 2010-05-06 スリーエム イノベイティブ プロパティズ カンパニー ナノ粒子の製造方法
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CN101113078B (zh) * 2007-07-10 2011-02-02 程道远 新型玻璃防霉隔离粉
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
WO2009085731A1 (en) * 2007-12-21 2009-07-09 3M Innovative Properties Company Process for producing nanoparticles
DE102008020701A1 (de) * 2008-04-24 2009-10-29 Bayer Technology Services Gmbh Formulierung mit reduzierter Hygroskopizität
CN102076784A (zh) * 2008-05-08 2011-05-25 3M创新有限公司 表面改性的纳米粒子
WO2009142852A2 (en) * 2008-05-22 2009-11-26 3M Innovative Properties Company Process for manufacturing flowable powder drug compositions
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
WO2009158300A1 (en) 2008-06-26 2009-12-30 3M Innovative Properties Company Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2309984B1 (en) * 2008-07-02 2018-04-11 3M Innovative Properties Company Method of making a dry powder pharmaceutical composition
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US20100116172A1 (en) * 2008-11-13 2010-05-13 3M Innovative Properties Company Method for making a dispersion
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8741819B2 (en) 2008-12-30 2014-06-03 3M Innovative Properties Company Composite particles and method of forming
US20110257054A1 (en) 2008-12-30 2011-10-20 Baran Jr Jimmie R Lubricant Composition and Method of Forming
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP2429495A4 (en) 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITION WITH IMPROVED PHARMACOKINETICS
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US20100323067A1 (en) * 2009-06-19 2010-12-23 Hershey Foods Corporation Temperature resistant chocolate composition and method
US20120100373A1 (en) 2009-06-26 2012-04-26 Shinbach Madeline P Method of milling particles with nanoparticles and milled free-flowing powder
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
CN102714071A (zh) 2009-11-20 2012-10-03 3M创新有限公司 包含其上共价连接有表面改性的纳米粒子的导电粒子的组合物、以及制备方法
WO2011063222A2 (en) * 2009-11-20 2011-05-26 3M Innovative Properties Company Inorganic pigment compositions comprising surface-modified nanoparticles, and methods of making
SG181046A1 (en) 2009-12-03 2012-07-30 3M Innovative Properties Co Method of electrostatic deposition of particles, abrasive grain and articles
US8834618B2 (en) 2009-12-03 2014-09-16 3M Innovative Properties Company Method of inhibiting water adsorption of powder by addition of hydrophobic nanoparticles
JP6016797B2 (ja) * 2010-10-04 2016-10-26 スリーエム イノベイティブ プロパティズ カンパニー 疎水性ナノ粒子の添加による粒子の溶解速度の変更方法
EP2651651B1 (en) * 2010-12-17 2019-01-23 3M Innovative Properties Company Transfer article having multi-sized particles and methods
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
CN102810377A (zh) * 2011-05-31 2012-12-05 深圳出入境检验检疫局食品检验检疫技术中心 一种复合型磁性纳米的制备方法及在小分子提取及富集中的应用
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
RU2666963C2 (ru) 2012-04-13 2018-09-13 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Агрегированные частицы
CA3098386C (en) 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
MX369136B (es) 2013-03-15 2019-10-30 Mannkind Corp Composiciones de dicetopiperazina microcristalina y metodos.
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US20160228433A1 (en) * 2013-09-24 2016-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal dhe for the treatment of headache
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
JP6502359B2 (ja) * 2013-12-19 2019-04-17 スリーエム イノベイティブ プロパティズ カンパニー ナノ粒子粉末組成物及びその製造方法
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
JP6546386B2 (ja) * 2014-10-15 2019-07-17 株式会社アドマテックス 無機フィラー及びその製造方法、樹脂組成物、及び成形品
WO2016064405A1 (en) 2014-10-23 2016-04-28 3M Innovative Properties Company Composition of an insulating pvc substrate with nanoparticle treated filler
WO2017218476A2 (en) 2016-06-16 2017-12-21 3M Innovative Properties Company Nanoparticle filled barrier adhesive compositions
TWI617533B (zh) 2016-12-09 2018-03-11 財團法人工業技術研究院 表面改質陶瓷粉體及其應用
US20180362834A1 (en) 2017-06-16 2018-12-20 TenEx Technologies, LLC Compositions And Methods For Treating Subterranean Formations
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
KR20200115524A (ko) * 2018-02-06 2020-10-07 니신 푸즈 인코포레이티드 감자 전분 및 감자 전분 조성물
US11820844B2 (en) 2018-03-22 2023-11-21 3M Innovative Properties Company Charge-modified particles and methods of making the same
WO2019180619A1 (en) 2018-03-22 2019-09-26 3M Innovative Properties Company Modified aluminum nitride particles and methods of making the same
CA3122396A1 (en) 2018-12-11 2020-06-18 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
EP3785825A1 (en) 2019-08-30 2021-03-03 3M Innovative Properties Company Powder blend for use in additive manufacturing
CN111358773B (zh) * 2020-04-10 2021-03-30 广州南鑫药业有限公司 一种帕拉米韦干粉吸入剂及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801185A (en) 1952-05-16 1957-07-30 Du Pont Silica hydrosol powder
US4478876A (en) 1980-12-18 1984-10-23 General Electric Company Process of coating a substrate with an abrasion resistant ultraviolet curable composition
US4491508A (en) 1981-06-01 1985-01-01 General Electric Company Method of preparing curable coating composition from alcohol, colloidal silica, silylacrylate and multiacrylate monomer
US4455205A (en) 1981-06-01 1984-06-19 General Electric Company UV Curable polysiloxane from colloidal silica, methacryloyl silane, diacrylate, resorcinol monobenzoate and photoinitiator
US4486504A (en) 1982-03-19 1984-12-04 General Electric Company Solventless, ultraviolet radiation-curable silicone coating compositions
US4522958A (en) 1983-09-06 1985-06-11 Ppg Industries, Inc. High-solids coating composition for improved rheology control containing chemically modified inorganic microparticles
US4767726A (en) 1987-01-12 1988-08-30 Minnesota Mining And Manufacturing Company Glass microbubbles
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5037579A (en) 1990-02-12 1991-08-06 Nalco Chemical Company Hydrothermal process for producing zirconia sol
US5258225A (en) 1990-02-16 1993-11-02 General Electric Company Acrylic coated thermoplastic substrate
JPH09512781A (ja) 1994-04-25 1997-12-22 ミネソタ マイニング アンド マニュファクチャリング カンパニー 溶融された粒子を含む組成物及びその製造方法
DE19616781A1 (de) 1996-04-26 1997-11-06 Degussa Silanisierte Kieselsäure
ATE234103T1 (de) 1997-12-22 2003-03-15 Schering Corp Feste, oral verabreichbare ribavirin dosisformen und verfahren zu deren herstellung
US6329058B1 (en) 1998-07-30 2001-12-11 3M Innovative Properties Company Nanosize metal oxide particles for producing transparent metal oxide colloids and ceramers
GB9822523D0 (en) * 1998-10-15 1998-12-09 Courtaulds Coatings Holdings Powder coating compositions
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6585957B1 (en) * 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US7758888B2 (en) * 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
US6586483B2 (en) 2001-01-08 2003-07-01 3M Innovative Properties Company Foam including surface-modified nanoparticles
CN1263808C (zh) * 2001-02-27 2006-07-12 清华大学 一种微米颗粒表面纳米化改性方法
AU2002334939A1 (en) * 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
WO2004081222A2 (en) * 2003-03-14 2004-09-23 Sol-Gel Technologies Ltd. Agent-encapsulating micro- and nanoparticles, methods for preparation of same and products containing same
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions

Also Published As

Publication number Publication date
US20080286362A1 (en) 2008-11-20
CN101243130B (zh) 2011-12-07
EP1917301B1 (en) 2014-04-23
CA2617909A1 (en) 2007-02-15
US8062670B2 (en) 2011-11-22
JP2009503104A (ja) 2009-01-29
CA2617909C (en) 2014-02-04
JP5694643B2 (ja) 2015-04-01
EP1917301A1 (en) 2008-05-07
JP2013100352A (ja) 2013-05-23
CN101243130A (zh) 2008-08-13
AU2006278571A1 (en) 2007-02-15
WO2007019229A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
AU2006278571B2 (en) Compositions exhibiting improved flowability
EP2309978B1 (en) Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof
EP2296628B1 (en) Process for manufacturing flowable powder drug compositions
EP2309984B1 (en) Method of making a dry powder pharmaceutical composition
CA2195065C (en) Inhalation composition
CN1913873B (zh) 包含装在防水容器中的tiotropium的医学产品
US7459146B2 (en) Stabilized aerosol dispersions
AP1374A (en) Aerosolizable particles resistant to hygroscopic growth.
PL186757B1 (pl) Proszek do stosowania w suchym inhalatorze proszkowym i sposób wytwarzania proszku do stosowania w suchym inhalatorze proszkowym
CN101098671A (zh) 最少化表面上的粉末滞留量
Vanderbist et al. Optimization of a dry powder inhaler formulation of nacystelyn, a new mucoactive agent
HK1116391A (en) Minimizing powder retention on surfaces

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired